이상반응 보고
| VAERS ID | 2247517 |
|---|---|
| 성별 | 남성 |
| 나이 | 69세 |
| 주 코드 | FR |
| 제약회사 | MODERNA |
| 로트 번호 | 050F21A_1110124 |
| 예방접종 횟수 | 3 |
| 접종일 | 2022-01-12 |
| 발병일 | 2022-04-04 |
| 상태 |
증상
- 말초 부종(Peripheral swelling)
- 호흡곤란(Dyspnoea)
- 식욕 감소(Decreased appetite)
- 쌕쌕거림(Wheezing)
- 근육 약화(Muscular weakness)
이환 중 질병
지병
기타 의료
이전 예방접종
알레르기
임상 검사
증상 상세
Loss of appetite; Swollen feet, wheezing when walking and shortness of breath; Swollen feet, wheezing when walking and shortness of breath; Swollen feet, wheezing when walking and shortness of breath; Limb weakness; This regulatory authority case was reported by an other health care professional and describes the occurrence of DECREASED APPETITE (Loss of appetite), PERIPHERAL SWELLING (Swollen feet, wheezing when walking and shortness of breath), WHEEZING (Swollen feet, wheezing when walking and shortness of breath), DYSPNOEA (Swollen feet, wheezing when walking and shortness of breath) and MUSCULAR WEAKNESS (Limb weakness) in a 69-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no.
050F21A_1110124-CDC) for COVID-19 vaccination.
No Medical History information was reported.
On 12-Jan-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.
On 04-Apr-2022, the patient experienced DECREASED APPETITE (Loss of appetite) (seriousness criterion medically significant), PERIPHERAL SWELLING (Swollen feet, wheezing when walking and shortness of breath) (seriousness criterion medically significant), WHEEZING (Swollen feet, wheezing when walking and shortness of breath) (seriousness criterion medically significant), DYSPNOEA (Swollen feet, wheezing when walking and shortness of breath) (seriousness criterion medically significant) and MUSCULAR WEAKNESS (Limb weakness) (seriousness criterion medically significant).
At the time of the report, DECREASED APPETITE (Loss of appetite), PERIPHERAL SWELLING (Swollen feet, wheezing when walking and shortness of breath), WHEEZING (Swollen feet, wheezing when walking and shortness of breath), DYSPNOEA (Swollen feet, wheezing when walking and shortness of breath) and MUSCULAR WEAKNESS (Limb weakness) was resolving.
For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
No concomitant medications were reported.
After being vaccinated with Moderna vaccine on 12-Jan-2022, patient suffered from loss of appetite, general weakness, swollen feet, asthma when walking and shortness of breath.
He needed to breathe hard and went to the hospital for consultations.
Later, the patient was referred to hospital for cardiac catheter stent, but the conditions was not improved.
The patient complained that, one cardiac stent was implanted and as the symptoms was not improved, blood sample was drawn and tested and hyperthyroidism was found and regular medication.
Treatment information was not provided.
Company Comment: This regulatory case concerns a 69-year-old male patient with no reported medical history, who experienced the unexpected serious (medically significant) events of Decreased appetite, Peripheral swelling, Wheezing, Dyspnoea and Muscular weakness that occurred 2 months and 23 days after receiving the third dose of mRNA-1273 vaccine.
Patient went for consultations and was later referred to a hospital for cardiac catheter stent which did not improve symptoms.
Blood sample taken revealed hyperthyroidism for which medication was started.
There is no information provided on the previous 2 doses of COVID-19 vaccination.
The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.
The case seriousness was assessed as per Regulatory Authority report.
; Sender's Comments: This regulatory case concerns a 69-year-old male patient with no reported medical history, who experienced the unexpected serious (medically significant) events of Decreased appetite, Peripheral swelling, Wheezing, Dyspnoea and Muscular weakness that occurred 2 months and 23 days after receiving the third dose of mRNA-1273 vaccine.
Patient went for consultations and was later referred to a hospital for cardiac catheter stent which did not improve symptoms.
Blood sample taken revealed hyperthyroidism for which medication was started.
There is no information provided on the previous 2 doses of COVID-19 vaccination.
The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.
The case seriousness was assessed as per Regulatory Authority report.